| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that buprenorphine extended-release injection (BUP-ER) be reimbursed for the management of moderate to severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product, if the following conditions are met: Conditions for Reimbursement : Initiation criteria 1. Patients must be induced and stabilized on an equivalent of 8 mg to 24 mg per day of transmucosal buprenorphine for a minimum of seven days. Administration conditions : 1. Patients are under the care of a health care provider with experience in the diagnosis and management of opioid use disorder. 2. As stated in the Health Canada indication, BUP-ER should be used as part of a complete treatment plan that includes counselling and psychosocial support. 3. As stated in the Health Canada indication, BUP-ER must be administered subcutaneously in the abdominal region by a healthcare provider. Pricing conditions : 1. A reduction in price
|
|---|